DE60024947D1 - Chinolin-4-ylderivate und ihre Verwendung als NMDA-Rezeptor Subtyp Blocker - Google Patents

Chinolin-4-ylderivate und ihre Verwendung als NMDA-Rezeptor Subtyp Blocker

Info

Publication number
DE60024947D1
DE60024947D1 DE60024947T DE60024947T DE60024947D1 DE 60024947 D1 DE60024947 D1 DE 60024947D1 DE 60024947 T DE60024947 T DE 60024947T DE 60024947 T DE60024947 T DE 60024947T DE 60024947 D1 DE60024947 D1 DE 60024947D1
Authority
DE
Germany
Prior art keywords
quinolin
derivatives
nmda receptor
receptor subtype
subtype blockers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60024947T
Other languages
English (en)
Other versions
DE60024947T2 (de
Inventor
Alexander Alanine
Serge Burner
Bernd Buettelmann
Neidhart Marie-Paule Heitz
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60024947D1 publication Critical patent/DE60024947D1/de
Publication of DE60024947T2 publication Critical patent/DE60024947T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
DE60024947T 1999-10-08 2000-10-02 Chinolin-4-yl derivate und ihre Verwendung als NMDA-Rezeptor Subtyp Blocker Expired - Lifetime DE60024947T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99120131 1999-10-08
EP99120131 1999-10-08

Publications (2)

Publication Number Publication Date
DE60024947D1 true DE60024947D1 (de) 2006-01-26
DE60024947T2 DE60024947T2 (de) 2006-09-21

Family

ID=8239160

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60024947T Expired - Lifetime DE60024947T2 (de) 1999-10-08 2000-10-02 Chinolin-4-yl derivate und ihre Verwendung als NMDA-Rezeptor Subtyp Blocker

Country Status (26)

Country Link
US (1) US6339093B1 (de)
EP (1) EP1090917B1 (de)
JP (1) JP3385318B2 (de)
KR (1) KR100398562B1 (de)
CN (1) CN1162424C (de)
AR (1) AR032601A1 (de)
AT (1) ATE313538T1 (de)
AU (1) AU777881B2 (de)
BR (1) BR0004709A (de)
CA (1) CA2322309C (de)
DE (1) DE60024947T2 (de)
DK (1) DK1090917T3 (de)
EG (1) EG23872A (de)
ES (1) ES2254095T3 (de)
HR (1) HRP20000652A2 (de)
HU (1) HUP0003938A2 (de)
ID (1) ID27526A (de)
IL (1) IL138916A0 (de)
MA (1) MA26753A1 (de)
MX (1) MXPA00009771A (de)
NO (1) NO20005031L (de)
NZ (1) NZ507303A (de)
PE (1) PE20010660A1 (de)
PL (1) PL343057A1 (de)
TR (1) TR200002893A3 (de)
ZA (1) ZA200005447B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
US7375136B2 (en) * 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
US6831087B2 (en) * 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
PT2167469E (pt) * 2007-06-18 2012-11-20 Richter Gedeon Nyrt Derivados de sulfonil-quinoleína
US8420680B2 (en) * 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
CA2700841A1 (en) * 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
JP6969800B2 (ja) * 2016-05-04 2021-11-24 ジェノシアンス ファルマ 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
EP3558318B1 (de) 2016-12-22 2023-12-20 Novartis AG Nmda-rezeptor-modulatoren und verwendungen davon
IL280474B2 (en) 2018-08-03 2023-09-01 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and their uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8409745D0 (en) * 1984-04-14 1984-05-23 Beecham Group Plc Active compounds
US4560692A (en) * 1984-07-18 1985-12-24 Hoffmann-La Roche Inc. 4-Piperidino-2-phenylquinolines
GB8716972D0 (en) * 1987-07-17 1987-08-26 Pfizer Ltd Treatment of cardiac arrhythmias
JPH0262875A (ja) 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
US4992448A (en) * 1989-10-24 1991-02-12 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
US5304554A (en) * 1990-04-27 1994-04-19 Emory University 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation
GB9203798D0 (en) * 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
GB9305644D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
US5567718A (en) * 1994-08-11 1996-10-22 Hoechst Marion Roussel Inc. 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives

Also Published As

Publication number Publication date
CN1162424C (zh) 2004-08-18
EP1090917A1 (de) 2001-04-11
EP1090917B1 (de) 2005-12-21
ID27526A (id) 2001-04-12
CA2322309C (en) 2008-05-20
ATE313538T1 (de) 2006-01-15
TR200002893A2 (tr) 2001-04-20
AU777881B2 (en) 2004-11-04
ES2254095T3 (es) 2006-06-16
BR0004709A (pt) 2001-06-12
US6339093B1 (en) 2002-01-15
NO20005031D0 (no) 2000-10-06
CA2322309A1 (en) 2001-04-08
PL343057A1 (en) 2001-04-09
CN1304936A (zh) 2001-07-25
PE20010660A1 (es) 2001-06-26
EG23872A (en) 2007-11-27
HUP0003938A2 (hu) 2002-11-28
ZA200005447B (en) 2001-04-09
KR100398562B1 (ko) 2003-09-19
KR20010050915A (ko) 2001-06-25
DK1090917T3 (da) 2006-04-24
IL138916A0 (en) 2001-11-25
DE60024947T2 (de) 2006-09-21
NZ507303A (en) 2002-09-27
HRP20000652A2 (en) 2001-12-31
HU0003938D0 (en) 2000-12-28
AU6410000A (en) 2001-04-12
MA26753A1 (fr) 2004-12-20
MXPA00009771A (es) 2002-10-23
NO20005031L (no) 2001-04-09
JP3385318B2 (ja) 2003-03-10
TR200002893A3 (tr) 2001-04-20
AR032601A1 (es) 2003-11-19
JP2001114777A (ja) 2001-04-24

Similar Documents

Publication Publication Date Title
DE69925730D1 (de) 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
DE60015296D1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
ATE253067T1 (de) Diazabicyloderivate als nikotin-acetylcholin- rezeptorliganden
EG24590A (en) Benzimidazole and pyridylimidazole derivative as ligands gabaa receptors
ATE279396T1 (de) Imidazolderivate und ihre verwendung als somatostatin rezeptorliganden
DE60001840T2 (de) Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
ATE403647T1 (de) Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden
DE60029007D1 (de) Quinazolin-derivate als vegf-hemmer
ATE299866T1 (de) Piperidinderivate verwendbar als ccr5 antagonisten
ATE375987T1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
ATE299865T1 (de) Piperazinderivate verwendbar als ccr5 antagonisten
IL156487A0 (en) Carbazole derivatives and their use as neuropeptide y5 receptor ligands
DE60112607D1 (de) 3-arylindolderivate und deren verwendung als cb2-rezeptoragonisten
DE60106607D1 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
ATE250035T1 (de) Chinolin- und chinazolin-derivate als crf antagonisten
DE60008262D1 (de) Piperazinderivate als 5-ht1b antagonisten
DE60024947D1 (de) Chinolin-4-ylderivate und ihre Verwendung als NMDA-Rezeptor Subtyp Blocker
ATE309240T1 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
DE69816290D1 (de) Chinolin-4-carboxamidderivate als nk-2 und nk-3 rezeptor antagonisten
EE200200135A (et) D4 antagonistidena toimivad tienoisoksasolüül- jatienüülpürrasolüülfenoksü-asendatud propüülderivaadid
ATE395333T1 (de) 4-phenylpiperazinyl, -piperidinyl und - tetrahydropyridyl-derivate als dopamin d4- antagonisten
ATE293619T1 (de) Pyridinderivate als nmda-rezeptorliganden
AU2002215043A1 (en) Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
ATE353325T1 (de) 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-metho y-phenoxy)-2-pyridyl-pyrimidin derivate, deren herstellung und deren verwendung als endothelin rezeptor antagonisten
DE60015471D1 (de) Chinolin-4-yl-derivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition